Bottles of Purdue Pharma L.P. OxyContin medication sit on a pharmacy shelf in Provo, Utah. (Photo: George Frey/Bloomberg)
The Wall Street Journal said the company has agreed to pay $270 million to settle the Oklahoma claims.
The reports come a day after the Oklahoma Supreme Court denied the company's efforts to delay what would have been the first trial focusing on the opioid manufacturer's conduct. The trial had been set to being May 28 in Oklahoma.
Bankruptcy rumors began infiltrating the Oklahoma trial last month, and in early March Reuters first reported that Purdue was exploring bankruptcy to address its growing liabilities over the opioid epidemic. A Chapter 11 filing would halt the lawsuits, folding them into bankruptcy court. Purdue then sought to delay the trial until September, citing a "belated tidal wave of documents."
Accused of marketing drugs as safe, nonaddictive
The case, filed on 2017, alleged that Purdue and two other opioid manufacturers, Johnson & Johnson's Janssen Pharmaceuticals Inc. and Teva Pharmaceuticals USA, helped create an epidemic over the prescription painkillers by marketing them as a safe and nonaddictive treatment for chronic pain.
Purdue's lawyers in the case are Sanford Coats of Crowe & Dunlevy in Oklahoma City and Mark Cheffo, a partner in Dechert's New York office.
Neither Purdue nor the Oklahoma Attorney General's Office immediately returned a call for comment Tuesday morning.
This is a developing report.
© Touchpoint Markets, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to TMSalesOperations@arc-network.com. For more information visit Asset & Logo Licensing.